Vivek Narayan

3.8k total citations · 1 hit paper
99 papers, 1.8k citations indexed

About

Vivek Narayan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Vivek Narayan has authored 99 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 22 papers in Cancer Research. Recurrent topics in Vivek Narayan's work include Prostate Cancer Treatment and Research (25 papers), Renal cell carcinoma treatment (17 papers) and Cancer, Hypoxia, and Metabolism (14 papers). Vivek Narayan is often cited by papers focused on Prostate Cancer Treatment and Research (25 papers), Renal cell carcinoma treatment (17 papers) and Cancer, Hypoxia, and Metabolism (14 papers). Vivek Narayan collaborates with scholars based in United States, France and Denmark. Vivek Narayan's co-authors include Bonnie Ky, Russell K. Pachynski, David J. Vaughn, Naomi B. Haas, Yanhua Hu, Padmanee Sharma, Abdel Saci, Marika Ciprotti, Akash Patnaik and Gwénaëlle Gravis and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Vivek Narayan

93 papers receiving 1.8k citations

Hit Papers

A comparison of sunitinib with cabozantinib, crizotinib, ... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
    2021 170 citations Vivek Narayan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vivek Narayan United States 22 837 830 509 333 327 99 1.8k
Jay M. Lee United States 24 914 1.1× 636 0.8× 486 1.0× 160 0.5× 249 0.8× 89 2.0k
Tatsuhiro Shibata Japan 15 551 0.7× 266 0.3× 522 1.0× 295 0.9× 282 0.9× 41 1.4k
Michael V. Di Maria United States 15 746 0.9× 955 1.2× 471 0.9× 185 0.6× 197 0.6× 40 1.7k
Alessandra Fabbri Italy 21 1.0k 1.2× 744 0.9× 622 1.2× 122 0.4× 369 1.1× 64 2.1k
Ananth Kadambi United States 10 749 0.9× 315 0.4× 1.0k 2.0× 137 0.4× 367 1.1× 25 2.1k
David D. Chism United States 17 554 0.7× 490 0.6× 687 1.3× 117 0.4× 232 0.7× 30 1.7k
Lingling Du United States 18 335 0.4× 855 1.0× 567 1.1× 424 1.3× 291 0.9× 46 1.6k
Thomas Krahn Germany 18 593 0.7× 215 0.3× 340 0.7× 416 1.2× 380 1.2× 45 1.6k
Florian Heitz Germany 33 1.1k 1.3× 540 0.7× 482 0.9× 153 0.5× 431 1.3× 180 3.2k
Keaton Jones United Kingdom 17 691 0.8× 263 0.3× 320 0.6× 121 0.4× 188 0.6× 28 1.6k

Countries citing papers authored by Vivek Narayan

Since Specialization
Citations

This map shows the geographic impact of Vivek Narayan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Narayan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Narayan more than expected).

Fields of papers citing papers by Vivek Narayan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek Narayan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Narayan. The network helps show where Vivek Narayan may publish in the future.

Co-authorship network of co-authors of Vivek Narayan

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Narayan. A scholar is included among the top collaborators of Vivek Narayan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Narayan. Vivek Narayan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Eyrich, Nicholas W., et al.. (2026). Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate Cancer. JU Open Plus. 4(2). e00019–e00019. 1 indexed citations
3.
Srinivasan, Ramaprasad, Othon Iliopoulos, Kathryn E. Beckermann, et al.. (2025). Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. The Lancet Oncology. 26(5). 571–582. 2 indexed citations
4.
5.
6.
Else, Tobias, Eric Jonasch, Othon Iliopoulos, et al.. (2024). Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clinical Cancer Research. 30(9). 1750–1757. 11 indexed citations
7.
Guerraty, Marie, Biniyam G. Demissei, Naomi B. Haas, et al.. (2024). Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy. Clinical Genitourinary Cancer. 22(4). 102107–102107. 1 indexed citations
8.
Gupta, Pradeep Kumar, Fernando Arias‐Mendoza, David Nelson, et al.. (2024). Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy. Cancers. 16(7). 1384–1384. 4 indexed citations
9.
Iliopoulos, Othon, Vivek Narayan, Kathryn E. Beckermann, et al.. (2024). Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. The Lancet Oncology. 25(10). 1325–1336. 16 indexed citations
10.
Suresh, Harsha Garadi, Henry N. Ward, Ian Jones, et al.. (2024). The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2. eLife. 13.
11.
Lin, John K., Emily Getzen, Qi Long, et al.. (2023). Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer. European Urology Oncology. 7(4). 794–803. 5 indexed citations
12.
Singh, Bhim, et al.. (2023). LM2L rule based adaptive filter controlled multi-functional SPV plant to enhance DG set utilization. Electric Power Systems Research. 222. 109506–109506. 2 indexed citations
13.
Narayan, Vivek, Othon Iliopoulos, Benjamin L. Maughan, et al.. (2023). SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY. Neuro-Oncology Advances. 5(Supplement_3). iii31–iii31. 1 indexed citations
14.
Narayan, Vivek, et al.. (2023). 1824P Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 34. S988–S988. 1 indexed citations
15.
Narayan, Vivek & Eric Jonasch. (2022). Systemic Therapy Development in Von Hippel–Lindau Disease: An Outsized Contribution from an Orphan Disease. Cancers. 14(21). 5313–5313. 6 indexed citations
16.
Jung, In-Young, Vivek Narayan, Andrew J. Rech, et al.. (2022). BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine. 14(670). eabn7336–eabn7336. 82 indexed citations
17.
Hahn, Virginia S., Kathleen W. Zhang, Lova Sun, et al.. (2021). Heart Failure With Targeted Cancer Therapies. Circulation Research. 128(10). 1576–1593. 46 indexed citations
18.
Yu, Shun, Anh N. Le, Emily Feld, et al.. (2021). A Natural Language Processing–Assisted Extraction System for Gleason Scores: Development and Usability Study. JMIR Cancer. 7(3). e27970–e27970. 7 indexed citations
19.
Thompson, Elizabeth, Biniyam G. Demissei, Amanda M. Smith, et al.. (2021). Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. JACC Basic to Translational Science. 7(1). 1–10. 7 indexed citations
20.
Narayan, Vivek, Stephen J. O’Keefe, Naomi B. Haas, et al.. (2017). Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3601–3609. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay M. Lee Breakdown of academic impact, for papers by Tatsuhiro Shibata Breakdown of academic impact, for papers by Michael V. Di Maria Breakdown of academic impact, for papers by Alessandra Fabbri Breakdown of academic impact, for papers by Ananth Kadambi Breakdown of academic impact, for papers by David D. Chism Breakdown of academic impact, for papers by Lingling Du Breakdown of academic impact, for papers by Thomas Krahn Breakdown of academic impact, for papers by Florian Heitz Breakdown of academic impact, for papers by Keaton Jones
Rankless by CCL
2026